Google partner and GlaxoSmithKline to join $700 million forces

Two of the world’s biggest tech and drug companies are joining forces to found an entirely new company called Galvani Bioelectrics based on bioelectronics research.

GlaxoSmithKline and Verily Life Sciences (which is under the umbrella of Google’s parent company, Alphabet) are set to spend more than $725 million on the new venture. They’ll work in both originator companies’ hometowns of London and San Francisco.

Bioelectronic medicine focuses on manipulating the body’s electrical impulses for therapeutic ends, instead of chemical or physical mechanisms.

Check out Forbes to see more business-end details of the deal. 

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup